To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)
Hypercholesterolemia
About this trial
This is an interventional treatment trial for Hypercholesterolemia
Eligibility Criteria
Inclusion Criteria: Patient with LDL-C of 130 through 190 mg/dL and Triglycerides less than or equal to 500 mg/dL Patient willing to be on a low-cholesterol diet Exclusion Criteria: Pregnant or lactating women or intending to become pregnant Patient with sensitivity or intolerance to ezetimibe, simvastatin, or ezetimibe/simvastatin combination tablet Patient with sensitivity or intolerance ro niacin, any component or niacin extended release or aspirin Patient for whom discontinuation of existing lipid-lowering therapy treatment poses an unacceptable risk
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Placebo Comparator
Part 1 - Arm 1
Part 1 -Arm 2
Part 1 - Arm 3
Part 2 - Arm 1
Part 2 - Arm 2
ezetimibe/simvastatin combination tablet + niacin (ER)
ezetimibe/simvastatin
Niacin (ER)
ezetimibe/simvastatin combination tablet + niacin (ER)
ezetimibe/simvastatin combination tablet + niacin (Pbo)